138 related articles for article (PubMed ID: 35905973)
1. Repurposing the Pentameric B-Subunit of Shiga Toxin for Gb3-Targeted Immunotherapy of Colorectal Cancer by Rhamnose Conjugation.
Liu Z; Li X; Lu Z; Qin X; Hong H; Zhou Z; Pieters RJ; Shi J; Wu Z
J Pharm Sci; 2022 Oct; 111(10):2719-2729. PubMed ID: 35905973
[TBL] [Abstract][Full Text] [Related]
2. Tumor delivery of ultrasound contrast agents using Shiga toxin B subunit.
Couture O; Dransart E; Dehay S; Nemati F; Decaudin D; Johannes L; Tanter M
Mol Imaging; 2011 Apr; 10(2):135-43. PubMed ID: 21439258
[TBL] [Abstract][Full Text] [Related]
3. Gastric Adenocarcinomas Express the Glycosphingolipid Gb3/CD77: Targeting of Gastric Cancer Cells with Shiga Toxin B-Subunit.
Geyer PE; Maak M; Nitsche U; Perl M; Novotny A; Slotta-Huspenina J; Dransart E; Holtorf A; Johannes L; Janssen KP
Mol Cancer Ther; 2016 May; 15(5):1008-17. PubMed ID: 26826119
[TBL] [Abstract][Full Text] [Related]
4. A Shiga Toxin B-Subunit-Based Lectibody Boosts T Cell Cytotoxicity towards Gb3-Positive Cancer Cells.
Tomisch J; Busse V; Rosato F; Makshakova ON; Salavei P; Kittel AS; Gillon E; Lataster L; Imberty A; Meléndez AV; Römer W
Cells; 2023 Jul; 12(14):. PubMed ID: 37508560
[TBL] [Abstract][Full Text] [Related]
5. Tumor Targeting with Bacterial Shiga Toxin B Subunit in Genetic Porcine Models for Colorectal Cancer and Osteosarcoma.
Ehrenfeld M; Schrade A; Flisikowska T; Perl M; Hirsch ND; Sichler A; Geyer L; Flisikowski K; Wilhelm D; Schober SJ; Johannes L; Schnieke A; Janssen KP
Mol Cancer Ther; 2022 Apr; 21(4):686-699. PubMed ID: 35086950
[TBL] [Abstract][Full Text] [Related]
6. Potent in vitro antitumor activity of B-subunit of Shiga toxin conjugated to the diphtheria toxin against breast cancer.
Mohseni Z; Sedighian H; Halabian R; Amani J; Behzadi E; Imani Fooladi AA
Eur J Pharmacol; 2021 May; 899():174057. PubMed ID: 33753109
[TBL] [Abstract][Full Text] [Related]
7. Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool.
Falguières T; Maak M; von Weyhern C; Sarr M; Sastre X; Poupon MF; Robine S; Johannes L; Janssen KP
Mol Cancer Ther; 2008 Aug; 7(8):2498-508. PubMed ID: 18687997
[TBL] [Abstract][Full Text] [Related]
8. Human breast cancer and lymph node metastases express Gb3 and can be targeted by STxB-vectorized chemotherapeutic compounds.
Stimmer L; Dehay S; Nemati F; Massonnet G; Richon S; Decaudin D; Klijanienko J; Johannes L
BMC Cancer; 2014 Dec; 14():916. PubMed ID: 25476116
[TBL] [Abstract][Full Text] [Related]
9. Differential recognition of lipid domains by two Gb3-binding lectins.
Schubert T; Sych T; Madl J; Xu M; Omidvar R; Patalag LJ; Ries A; Kettelhoit K; Brandel A; Mely Y; Steinem C; Werz DB; Thuenauer R; Römer W
Sci Rep; 2020 Jun; 10(1):9752. PubMed ID: 32546842
[TBL] [Abstract][Full Text] [Related]
10. Membrane invagination induced by Shiga toxin B-subunit: from molecular structure to tube formation.
Pezeshkian W; Hansen AG; Johannes L; Khandelia H; Shillcock JC; Kumar PB; Ipsen JH
Soft Matter; 2016 Jun; 12(23):5164-71. PubMed ID: 27070906
[TBL] [Abstract][Full Text] [Related]
11. A real-time cell-binding assay reveals dynamic features of STxB-Gb3 cointernalization and STxB-mediated cargo delivery into cancer cells.
Encarnação JC; Napolitano V; Opassi G; Danielson UH; Dubin G; Popowicz GM; Munier-Lehmann H; Buijs J; Andersson K; Björkelund H
FEBS Lett; 2020 Aug; 594(15):2406-2420. PubMed ID: 32473599
[TBL] [Abstract][Full Text] [Related]
12. Shiga toxin type 2 B subunit protects mice against toxin challenge when leashed and bundled by a stable pentameric coiled-coil molecule.
Tamaki Y; Harakuni T; Arakawa T
Vaccine; 2024 Mar; 42(7):1757-1767. PubMed ID: 38365487
[TBL] [Abstract][Full Text] [Related]
13. STxB as an Antigen Delivery Tool for Mucosal Vaccination.
Tartour E; Johannes L
Toxins (Basel); 2022 Mar; 14(3):. PubMed ID: 35324699
[TBL] [Abstract][Full Text] [Related]
14. Gb3-Coated Bovine Milk Exosomes as a Practical Neutralizer for Shiga Toxin.
Lu M; Zhu Y; Li D; Zhou Z; Lin H; Hong H; Shi J; Wu Z
ACS Appl Bio Mater; 2023 Dec; 6(12):5798-5808. PubMed ID: 37988327
[TBL] [Abstract][Full Text] [Related]
15. Shiga toxin and its use in targeted cancer therapy and imaging.
Engedal N; Skotland T; Torgersen ML; Sandvig K
Microb Biotechnol; 2011 Jan; 4(1):32-46. PubMed ID: 21255370
[TBL] [Abstract][Full Text] [Related]
16. Histidine-tagged shiga toxin B subunit binding assay: simple and specific determination of gb3 content in mammalian cells.
Shin IS; Nishikawa K; Maruyama H; Ishii S
Chem Pharm Bull (Tokyo); 2006 Apr; 54(4):522-7. PubMed ID: 16595957
[TBL] [Abstract][Full Text] [Related]
17. Targeted Shiga toxin-drug conjugates prepared via Cu-free click chemistry.
Kostova V; Dransart E; Azoulay M; Brulle L; Bai SK; Florent JC; Johannes L; Schmidt F
Bioorg Med Chem; 2015 Nov; 23(22):7150-7. PubMed ID: 26507432
[TBL] [Abstract][Full Text] [Related]
18. Shiga toxin binding alters lipid packing and the domain structure of Gb
Bosse M; Sibold J; Scheidt HA; Patalag LJ; Kettelhoit K; Ries A; Werz DB; Steinem C; Huster D
Phys Chem Chem Phys; 2019 Jul; 21(28):15630-15638. PubMed ID: 31268447
[TBL] [Abstract][Full Text] [Related]
19. Two-dimensional structures of the Shiga toxin B-subunit and of a chimera bound to the glycolipid receptor Gb3.
Hagnerelle X; Plisson C; Lambert O; Marco S; Rigaud JL; Johannes L; Lévy D
J Struct Biol; 2002 Aug; 139(2):113-21. PubMed ID: 12406693
[TBL] [Abstract][Full Text] [Related]
20. A new delivery system for auristatin in STxB-drug conjugate therapy.
Batisse C; Dransart E; Ait Sarkouh R; Brulle L; Bai SK; Godefroy S; Johannes L; Schmidt F
Eur J Med Chem; 2015 May; 95():483-91. PubMed ID: 25847766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
